News

The company expects to commence phase 1/2 clinical trial in the second quarter of this year. AP32788 is an internally discovered product candidate designed as a targeted therapy

This trial will evaluate the safety and efficacy of SPI-2012 as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, and will serve as the basis for

The trial is testing RGN-259 (Thymosin beta 4), a sterile, preservative-free eye drop developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders. The

The application now will be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU). Bristol-Myers Squibb senior vice president, head

Under an agreement signed with Novartis in October 2014, Oxford BioMedica will undertake process development and manufacturing for the lentiviral vector associated with the new programme. Oxford BioMedica

In Europe, Coagadex (human coagulation factor X) is indicated for the treatment and preventive management of bleeding episodes and the control of bleeding during surgical procedures in patients

The meeting will be held on 29th March. Last November, the FDA classified the Nuplazid NDA as having priority review status with a target prescription drug user fee

The results from the initial trial are anticipated in the middle of this year, with the results from the second study expected soon thereafter. The FIT program features

The MoC with the Iran Food and Drug Administration, affiliated to the Ministry of Health and Medical Education, is aimed at initiating talks to explore the possibilities in